Takeda enters settlement with Watson over Actos patent challenge; pays milestone in Affymax deal
In what is another deal that is designed to delay the entry of a copy drug on to the US market, Watson Pharmaceuticals says that it has reached a settlement agreement with Japan's largest drugmaker Takeda, and its US subsidiary Takeda Pharmaceuticals North America, resolving outstanding patent litigation related to Watson's generic equivalent version of the type 2 diabetes drug Actos (pioglitazone) 15mg, 30mg and 45mg tablets.
Deals of this nature, dubbed 'pay-to-delay' or 'sweetheart' accords, are the subject of scrutiny in both the USA and Europe, where they are seen as preventing the arrival of cheaper generic drug copies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze